• 1. Alternative donor substrates for inverting and retaining glycosyltransferases?
  Luke L. Lairson,Warren W. Wakarchuk Chem. Commun., 2007, 365-367
• 2. An analysis of the WTC fires using CIB correlations and simple modeling
  JGQuintiere
• 3. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549
• 4. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002
• 5. Alumina grafted SBA-15 sustainable bifunctional catalysts for direct cross-coupling of benzylic alcohols to diarylmethanes?
  Chandran Rajendran,Govindaswamy Satishkumar,Charlotte Lang,Eric M. Gaigneaux Catal. Sci. Technol., 2020,10, 2583-2592

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Phenylpyridines

Introduction to 1,8-Naphthyridin-2-amine, 3-phenyl- (CAS No. 5174-94-7): Applications and Recent Research Developments

1,8-Naphthyridin-2-amine, 3-phenyl- (CAS No. 5174-94-7) is a heterocyclic organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal biology due to its versatile structural framework and potential biological activities. This compound belongs to the naphthyridine class of molecules, which are characterized by a fused bicyclic system containing nitrogen atoms at the 1 and 8 positions. The presence of an amine group at the 2-position and a phenyl substituent at the 3-position further enhances its chemical reactivity and functionalization possibilities, making it a valuable scaffold for drug discovery.

The chemical structure of 1,8-Naphthyridin-2-amine, 3-phenyl features a rigid aromatic system that can interact favorably with biological targets such as enzymes and receptors. The amine functionality at the 2-position serves as a nucleophilic center, enabling further derivatization through reactions such as coupling with carboxylic acids or aldehydes to form amides or ureas. Additionally, the phenyl group at the 3-position introduces hydrophobicity and can participate in π-stacking interactions, which are crucial for binding affinity in drug design.

In recent years, 1,8-Naphthyridin-2-amine, 3-phenyl has been explored as a key intermediate in the synthesis of various pharmacologically active compounds. Its unique structural properties make it an attractive candidate for developing novel therapeutic agents targeting a range of diseases. For instance, studies have demonstrated its utility in creating inhibitors of kinases and other enzymes involved in cancer pathways. The compound’s ability to modulate enzyme activity while maintaining high selectivity has positioned it as a promising candidate for further development.

One of the most compelling aspects of 1,8-Naphthyridin-2-amine, 3-phenyl is its role in the development of antiviral and antibacterial agents. Researchers have leveraged its scaffold to design molecules that interfere with viral replication or bacterial metabolic pathways. The amine group at the 2-position allows for modifications that enhance binding to viral proteases or integrases, while the phenyl ring can be tailored to optimize interactions with bacterial enzymes. These modifications have led to several promising candidates entering preclinical studies.

The synthesis of 1,8-Naphthyridin-2-amine, 3-phenyl typically involves multi-step organic reactions starting from readily available precursors. Common synthetic routes include cyclization reactions followed by functional group transformations to introduce the amine and phenyl substituents. Advances in synthetic methodologies have improved the efficiency and scalability of these processes, making it feasible to produce larger quantities for research and development purposes.

Recent research has also highlighted the potential of 1,8-Naphthyridin-2-amine, 3-phenyl in addressing neurological disorders. Its ability to cross the blood-brain barrier and interact with central nervous system targets has been exploited in designing treatments for conditions such as Alzheimer’s disease and Parkinson’s disease. The compound’s structural features allow it to modulate neurotransmitter systems or inhibit aberrant protein aggregation pathways associated with these diseases.

The pharmacokinetic properties of 1,8-Naphthyridin-2-amine, 3-phenyl are another area of active investigation. Studies have focused on optimizing its solubility, bioavailability, and metabolic stability to enhance its therapeutic efficacy. By fine-tuning its chemical structure through computational modeling and experimental validation, researchers aim to develop derivatives with improved pharmacokinetic profiles suitable for clinical use.

In conclusion,1,8-Naphthyridin-2-amine, 3-phenyl (CAS No. 5174-94-7) represents a structurally intriguing compound with significant potential in pharmaceutical applications. Its versatility as a scaffold for drug discovery continues to drive innovation across multiple therapeutic areas. As research progresses，the full therapeutic spectrum of this compound is expected to become more apparent，leading to novel treatments that address unmet medical needs.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)